Lapatinib Raw Materials Powder Lapatinib

CAS:231277-92-2

MF:C29H26ClFN4O4S

MW:581.06

EINECS:1806241-263-5

Specification: 99% min Lapatinib Powder

Sample:Lapatinib

Packaging:1kg/bag, 25kg/drum

Brand: Henrikang

Appearance:white

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

Lapatinib Powder Usage and Synthesis.

Lapatinib in combination with capecitabine is indicated for the treatment of advanced or metastatic breast cancer in patients with HER2 (ErbB-2 overexpression) who have previously received treatment including anthracycline, paclitaxel, and trastuzumab.

Uses and functions of Lapatinib.

Lapatinib is an oral small-molecule drug that is an antineoplastic drug used in combination with capecitabine to treat metastatic or advanced breast cancer that has been treated with prior HER-2 positive therapy, including anthracyclines, taxines, and trastuzumab.

The application of lapatinib as a prescription drug must be considered after the doctor's standardized diagnosis and treatment, and it is best to make it clear that it is the appropriate conditions for breast cancer before the use of this drug is considered. The application of lapatinib should be combined with a certain dose, the course of use, that is, to use the drug under the guidance of the doctor's prescription, but also according to the doctor's requirements of regular review and return visit, in order to make corresponding drug adjustment according to the treatment situation. In the process of medication, patients should pay attention to the following points:

1, it is best to consult the pharmacist at the medication window before medication, regarding the precautions of medication, adverse reactions, drug contraindications, to ensure the safety of medication while giving full play to the best therapeutic effect;

2. If any intolerable reactions or symptoms occur in the course of medication, consult the pharmacist or go to the hospital in time.

Pharmacological action of Lapatinib.

Lapatinib toluenesulfonic acid tablet is a small molecule 4-aniline-quinazoline-like receptor tyrosine kinase inhibitor that inhibits epidermal growth factor receptor (ErbB1) and human epidermal factor receptor 2 (ErbB2). Among the four breast cancer cell lines, BT474 and SKBr3 were sensitive to lapatinib, with semi-inhibitory concentrations of 25 and 32nmol/L, while MDA-MB-468 and T47D cell lines were not sensitive, and the semi-inhibitory concentrations were in the micromolar level. RT112 (high expression of ErbB1 and ErbB2) and J82 (low expression of ErbB1 and ErbB2) enhance the efficacy of cisplatin. Epidermal factor-driven tumor growth was inhibited in a variety of animals. Lapatinib is effective against trastuzumab resistant tumor cell lines.

Product method of Bulk Lapatinib Powder.